BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

Completed · Phase 1

Conditions studied: Tumor, Solid

In brief

A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors

Key facts

Study ID

NCT04196530

Run by

Eikon Therapeutics

People needed

40

Starts

2019-11-21

Expected to finish

2024-08-15

Last updated by the study team

2025-11-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Angeles Clinic — Los Angeles, California, United States
• Florida Cancer Specialists — Sarasota, Florida, United States
• Tennessee Oncology — Nashville, Tennessee, United States
• NEXT Oncology — San Antonio, Texas, United States
• South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.